With your own knowledge and the help of the following document:

Document 1 (Title: Enteric Viral Hepatitis: Pathogenesis and Prevention): Hepatitis A virus (HAV) represents a clinically significant cause of acute viral hepatitis with distinctive virological properties influencing its epidemiology, clinical manifestations, and preventive approaches. Molecular characterization identifies this pathogen as a member of the Picornaviridae family, featuring a single-stranded, positive-sense RNA genome enclosed within a non-enveloped icosahedral capsid approximately 27-32 nm in diameter. This structural configuration contrasts with DNA viruses causing hepatitis including hepatitis B virus, while sharing certain features with other picornaviruses such as poliovirus and rhinovirus. Transmission epidemiology demonstrates predominantly fecal-oral spread through contaminated food, water, or direct person-to-person contact, reflecting the virus's primary replication in hepatocytes with subsequent biliary excretion and high fecal viral concentrations. This transmission pattern explains the relationship between infection prevalence and sanitation infrastructure, with higher rates in regions with limited clean water access and inadequate sewage management. Clinical evolution typically follows a self-limited course without progression to chronicity, distinguishing HAV from hepatitis B and C viruses, which can establish persistent infection with potential progression to cirrhosis through chronic inflammatory mechanisms. While acute HAV infection occasionally causes severe manifestations, the virus demonstrates limited capacity for triggering the progressive fibrosis characteristic of chronic hepatotropic viral infections. Prevention strategies include both environmental interventions addressing transmission pathways and immunoprophylaxis through inactivated whole-virus vaccines providing durable protection through neutralizing antibody induction. These vaccination programs have demonstrated remarkable public health success in multiple national implementation contexts, substantially reducing HAV incidence in targeted populations through generation of long-lasting protective immunity.
Document 2 (Title: Viral Hepatitis: Epidemiology and Clinical Significance): Hepatitis B virus (HBV) represents a significant global health challenge with distinctive virological characteristics and diverse clinical manifestations. Virological classification identifies this pathogen as a member of the Hepadnaviridae family with a partially double-stranded DNA genome utilizing reverse transcriptase during replication, distinguishing it from RNA viruses causing related hepatic diseases. The virus demonstrates remarkable environmental stability, contributing to its documented role in nosocomial transmission through inadequately sterilized medical equipment, particularly in hemodialysis settings and during certain surgical procedures. Clinical course variability represents a hallmark feature, with acute infection potentially progressing to chronic hepatitis in 5-10% of immunocompetent adults and significantly higher percentages in perinatally infected individuals. This chronicity creates substantial long-term complications including cirrhosis and hepatocellular carcinoma through complex inflammatory and oncogenic mechanisms. Particularly concerning manifestations include fulminant hepatic failure occurring in approximately 0.5-1% of acute infections, characterized by massive hepatocellular necrosis, coagulopathy, and encephalopathy with mortality rates exceeding 80% without liver transplantation. Preventive approaches center on recombinant vaccine formulations containing HBsAg produced in yeast expression systems, representing an inactivated subunit vaccine rather than live attenuated preparations. This vaccination strategy has demonstrated remarkable success in reducing infection rates worldwide, though implementation challenges remain in certain regions. Clinical management continues to evolve with development of nucleoside/nucleotide analogs and immunomodulatory approaches for chronic infection, though therapeutic challenges persist particularly regarding viral clearance and prevention of long-term complications.
Document 3 (Title: Viral Pathogens in Reproductive Health): Viral sexually transmitted infections represent significant public health challenges with diverse pathogenic mechanisms, clinical manifestations, and epidemiological patterns. Herpes simplex virus type 2 (HSV-2) demonstrates efficient sexual transmission dynamics, with approximately 30-50% transmission risk per year in discordant monogamous relationships even during asymptomatic viral shedding periods. The virus establishes latency within sacral ganglia following primary infection, with periodic reactivation producing either symptomatic recurrences or subclinical viral shedding capable of transmission. Epidemiological studies document that genital herpes affects approximately 11-16% of adults globally, with higher prevalence in certain geographical regions and demographic groups. Human immunodeficiency virus (HIV) transmission through sexual contact represents another major global health concern, with risk varying by exposure type. Receptive anal intercourse carries the highest per-act transmission probability (approximately 1-2%), while vaginal and other sexual exposures present lower but significant risks further modified by viral load, concurrent ulcerative conditions, and prevention strategies including antiretroviral therapy. Other viral pathogens demonstrate variable sexual transmission potential based on their biological characteristics and primary transmission routes. Respiratory viruses including influenza predominantly spread through respiratory secretions rather than sexual contact, with no evidence supporting significant sexual transmission. Similarly, hepatitis A virus spreads primarily through fecal-oral routes rather than sexual contact in most epidemiological contexts, though certain sexual practices can facilitate transmission in specific situations. Enteroviruses including poliovirus spread predominantly through fecal-oral routes rather than sexual contact, with no significant epidemiological evidence supporting sexual transmission as a meaningful infection route. These distinctions in transmission dynamics inform appropriate preventive strategies, diagnostic approaches, and public health interventions for different viral pathogens.

Answer the following list question.
Question: Select the correct statement(s) regarding hepatitis B virus:
Options:
1. It can be responsible for nosocomial infections
2. It can be involved in chronic hepatitis
3. It is an RNA virus
4. It can be responsible for fulminant hepatitis
5. The vaccine used in France against this virus is a live attenuated vaccine

Respond strictly in valid JSON format as shown below:
{"answer": ["1", "3"]} ‚Üê if options 1 and 3 are correct
Only output the JSON object. Do not include explanations, labels, markdown, or any other text.